Related references
Note: Only part of the references are listed.Preclinical Efficacy of [V4Q5]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer
Juan Garona et al.
CANCER RESEARCH AND TREATMENT (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Increase in Ca2+ current by sustained cAMP levels enhances proliferation rate in GH3 cells
Andreia Laura Rodrigues et al.
LIFE SCIENCES (2018)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (vol 23, pg 313, 2018)
Christopher J. Ricketts et al.
CELL REPORTS (2018)
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Fouad T. Chebib et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Repurposing of Bromocriptine for Cancer Therapy
Ean-Jeong Seo et al.
FRONTIERS IN PHARMACOLOGY (2018)
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study
Volker Burst et al.
SUPPORTIVE CARE IN CANCER (2017)
Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials
Richard J. Gralla et al.
CANCER MEDICINE (2017)
Renal cell carcinoma
James J. Hsieh et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Peptide agonists of Vasopressin V2 receptor reduce expression of neuroendocrine Markers and Tumor growth in human lung and Prostate Tumor cells
Marina Pifano et al.
FRONTIERS IN ONCOLOGY (2017)
A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease
Vijayakumar R. Kakade et al.
Journal of Molecular Cell Biology (2016)
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
Fengju Chen et al.
CELL REPORTS (2016)
The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines
Alessandra Dicitore et al.
ENDOCRINE (2016)
Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice
Shailendra P. Singh et al.
DISEASE MODELS & MECHANISMS (2015)
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Paul B. Watkins et al.
DRUG SAFETY (2015)
The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models
Juan Garona et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease
Shixin Tao et al.
KIDNEY INTERNATIONAL (2015)
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease
Tamina Seeger-Nukpezah et al.
NATURE REVIEWS NEPHROLOGY (2015)
Targeting RAS-mutant Cancers: Is ERK the Key?
Meagan B. Ryan et al.
TRENDS IN CANCER (2015)
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Caleb F. Davis et al.
CANCER CELL (2014)
Hyponatremia Associated with Worse Outcomes in Metastatic Renal Cell Cancer: A Potential Target for Intervention?
Joaquim Bellmunt et al.
EUROPEAN UROLOGY (2014)
Cyclic adenosine 3′-5′-monophosphate (cAMP) exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependent protein kinase A (PKA) and exchange proteins directly activated by cAMP (Epac)
E. Vitali et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
Growth impairment of small-cell cancer by targeting pro-vasopressin with MAG-1 antibody
William G. North et al.
FRONTIERS IN ONCOLOGY (2014)
Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent
Pan Pantziarka et al.
ECANCERMEDICALSCIENCE (2014)
Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury
Miki Aihara et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model
Giselle V. Ripoll et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects
Susan E. Shoaf et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
Libero Santarpia et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Native MAG-1 antibody almost destroys human breast cancer xenografts
William G. North et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells
Nancy B. Iannucci et al.
FUTURE MEDICINAL CHEMISTRY (2011)
Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma
A. N. Jeppesen et al.
BRITISH JOURNAL OF CANCER (2010)
Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia
Tomas Berl et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
GSK3β Mediates Renal Response to Vasopressin by Modulating Adenylate Cyclase Activity
Reena Rao et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Quantitative phosphoproteomic analysis reveals cAMP/vasopressin-dependent signaling pathways in native renal thick ascending limb cells
Ruwan Gunaratne et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R)
Davide Bolignano et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo
Dan Huang et al.
CANCER RESEARCH (2008)
Cyclic AMP Inhibits the Proliferation of Thyroid Carcinoma Cell Lines through Regulation of CDK4 Phosphorylation
Ana Sofia Rocha et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption
Michelle Boone et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2008)
Tumor-Related Hyponatremia
Adedayo A. Onitilo et al.
CLINICAL MEDICINE & RESEARCH (2007)
Vasopressin receptor subtype 2 activation increases cell proliferation in the renal medulla of AQP1 null mice
Qi Cai et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Segmental disorders of the nephron: histopathological and imaging perspective
S. R. Prasad et al.
BRITISH JOURNAL OF RADIOLOGY (2007)
Nephrogenic diabetes insipidus in mice caused by deleting COOH-terminal tail of aquaporin-2
Peijun P. Shi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Sorafenib for the treatment of advanced renal cell carcinoma
Robert C. Kane et al.
CLINICAL CANCER RESEARCH (2006)
Provasopressin expression by breast cancer cells:: implications for growth and novel treatment strategies
BP Keegan et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Differential distribution of the vasopressin V2 receptor along the rat nephron during renal ontogeny and maturation
JM Sarmiento et al.
KIDNEY INTERNATIONAL (2005)
Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition
AC MacKinnon et al.
BRITISH JOURNAL OF CANCER (2005)
Membrane estrogen receptor-alpha levels in MCF-7 breast cancer cells predict cAMP and proliferation responses
D Zivadinovic et al.
BREAST CANCER RESEARCH (2005)
Cyclic AMP differentially regulates cell proliferation of normal human keratinocytes through ERK activation depending on the expression pattern of B-Raf
H Takahashi et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2004)
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype
T Yamaguchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway
C Péqueux et al.
ENDOCRINE-RELATED CANCER (2004)
Arginine vasopressin inhibition of cyclin D1 gene expression blocks the cell cycle and cell proliferation in the mouse Y1 adrenocortical tumor cell line
TT Schwindt et al.
BIOCHEMISTRY (2003)
Increased lactotrophs despite decreased somatotrophs in the dwarf (dw/dw) rat:: a defect in the regulation of lactotroph/somatotroph cell fate?
T Tierney et al.
JOURNAL OF ENDOCRINOLOGY (2002)
Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation
S Giron et al.
JOURNAL OF SURGICAL ONCOLOGY (2002)
Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression
TJ Shaw et al.
EXPERIMENTAL CELL RESEARCH (2002)
8-Cl-cAMP induces cell cycle-specific apoptosis ln human cancer cells
SN Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Autocrine and paracrine signaling through neuropeptide receptors in human cancer
LE Heasley
ONCOGENE (2001)
Mediators of the mitogenic action of human V1 vascular vasopressin receptors
M Thibonnier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2000)
Gene regulation of vasopressin and vasopressin receptors in cancer
WG North
EXPERIMENTAL PHYSIOLOGY (2000)
Share Paper
